Deepinder Goyal’s 'Continue' Unveils $25 Million Fund for Human Ageing Research

In a move that blends philanthropy with scientific curiosity, Zomato founder and CEO Deepinder Goyal has unveiled a $25 million research fund, fully financed from his personal wealth, to support pioneering studies on human ageing. 

Announced via X, the initiative called Continue Research expands on his 2-year-old project, Continue, which aims to explore simpler biological questions that could transform how humans understand and manage ageing.

Funding Model and Research Goals

The $25 million Continue Research Fund will provide 2 categories of grants:

• Moonshots: between $50,000 and $250,000 for high-risk, early-stage ideas.
• Deep Dives: between $250,000 and $2 million for studies testing key hypotheses over one to three years.

Every funded project must make its findings, including raw data, protocols, and failed experiments, open source and publicly accessible. The initiative will not demand prior publications or impose bureaucratic oversight, focusing instead on scientific curiosity and transparency.

As per the press release, Goyal emphasised that Continue is neither a company nor a startup but a research team and seed fund for the next phase of human existence. He added that its goal is to defeat short-termism. 

Vision and Philosophy

Goyal’s philosophy goes beyond biology. He connects ageing research with societal responsibility, arguing that humanity’s short lifespans lead to reckless decision-making from climate change to underinvestment in education and research.

Read More: Deepinder Goyal-Backed LAT Aerospace Sets Up Bengaluru R&D Hub to Build Gas Turbine Engines!

Conclusion

With Continue Research, Deepinder Goyal joins a growing global movement of tech entrepreneurs investing personally in longevity science. His focus on open access and simple-question biology could help reshape the future of ageing research, not for immediate gain, but for generations ahead.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.